Exactech, Inc. (NASDAQ:EXAC) Director James G. Binch sold 747 shares of the business’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $28.40, for a total value of $21,214.80. Following the sale, the director now owns 3,554 shares in the company, valued at $100,933.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of Exactech, Inc. (NASDAQ EXAC) opened at 29.95 on Friday. The stock has a 50 day moving average price of $29.41 and a 200 day moving average price of $28.11. Exactech, Inc. has a 12 month low of $22.20 and a 12 month high of $31.90. The stock has a market capitalization of $429.72 million, a P/E ratio of 575.96 and a beta of 1.02.
Exactech (NASDAQ:EXAC) last released its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.33 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.33. The firm had revenue of $67.30 million during the quarter, compared to analysts’ expectations of $67.75 million. Exactech had a return on equity of 7.39% and a net margin of 0.30%. The business’s revenue for the quarter was up 1.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.31 earnings per share. On average, analysts anticipate that Exactech, Inc. will post $1.29 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.com-unik.info/2017/08/19/exactech-inc-nasdaqexac-director-james-g-binch-sells-747-shares-of-stock-updated.html.
Several brokerages have recently issued reports on EXAC. BidaskClub upgraded Exactech from a “sell” rating to a “hold” rating in a research report on Friday. Gabelli restated a “buy” rating on shares of Exactech in a research report on Monday, July 31st. TheStreet upgraded Exactech from a “c+” rating to a “b” rating in a research report on Tuesday, April 25th. Finally, Zacks Investment Research upgraded Exactech from a “sell” rating to a “hold” rating in a research report on Tuesday, April 25th.
A number of hedge funds have recently added to or reduced their stakes in the stock. Gamco Investors INC. ET AL bought a new position in Exactech during the second quarter valued at $18,463,000. Thomson Horstmann & Bryant Inc. acquired a new position in Exactech during the first quarter worth approximately $4,857,000. Foundry Partners LLC raised its position in Exactech by 205.9% in the first quarter. Foundry Partners LLC now owns 155,436 shares of the medical equipment provider’s stock worth $3,917,000 after buying an additional 104,625 shares during the last quarter. FMR LLC raised its position in Exactech by 51.6% in the second quarter. FMR LLC now owns 251,876 shares of the medical equipment provider’s stock worth $7,506,000 after buying an additional 85,709 shares during the last quarter. Finally, Royce & Associates LP raised its position in Exactech by 21.1% in the first quarter. Royce & Associates LP now owns 290,889 shares of the medical equipment provider’s stock worth $7,330,000 after buying an additional 50,761 shares during the last quarter. 64.05% of the stock is owned by hedge funds and other institutional investors.
Exactech Company Profile
Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.
What are top analysts saying about Exactech Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Exactech Inc. and related companies.